The FDA issued an approvable letter for EPIX Pharmaceuticals Inc.'s imaging agent MS-325, but it has required additional clinical studies before it will grant marketing clearance. (BioWorld Today)

With increased revenues of 23 percent in the fourth quarter, Genzyme Corp. exceeded analyst expectations, ending the year with two major acquisitions under its belt and an FDA approval for Clolar. (BioWorld Today)

While Genentech Inc. logged a 43 percent jump in total product sales for 2004, analysts scrutinized the company's sales of Avastin, calling them modest and lethargic at best. (BioWorld Today)

Providing new hope for breast cancer patients, Abraxane soon will offer the antitumor benefits, without the toxic solvent side effects, of paclitaxel. (BioWorld Today)